News Novartis two for two as ianalumab scores again Novartis' ianalumab has delivered another win in primary immune thrombocytopenia, its second win in autoimmune diseases in 24 hours.
News MorphoSys takeover delivers phase 3 win for Novartis A drug for autoimmune disease Sjögren's syndrome, claimed by Novartis when it bought MorphoSys, could soon be filed for approval.
News More pharma M&A as Novartis snaps up MorphoSys for $2.9bn Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around
News Zymeworks cuts deal to buy Theravance for $929m in cash Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
